To include your compound in the COVID-19 Resource Center, submit it here.

Novartis discontinues Tasigna trial in GIST

Novartis AG (NYSE:NVS; SIX:NOVN) discontinued the Phase III ENESTg1 trial of Tasigna nilotinib as first-line treatment for gastrointestinal

Read the full 182 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE